美国美国食品药品监督管理局周四永久取消了对米非司酮药物的限制，该限制要求提供者亲自配药，允许通过邮件递送。

这一决定取决于州法律，州法律可以将这种行为定为犯罪。但美国食品和药物管理局的举措仍可能对女性产生重大影响，尤其是在农村地区，那里的女性可能更难找到诊所或医生亲自给药。

在最新的在线指南中，美国食品和药物管理局提到需要“减轻患者就诊的负担健康护理提供系统。"

堕胎权利团体对这一举措表示欢迎，但表示还需要做更多的工作来方便人们获得堕胎权。

“虽然今天的行动将对寻求护理的人有很大帮助，但其他障碍仍然存在，必须一劳永逸地消除，”最重要的联合主席命运·洛佩兹说。

杰夫·罗伯逊/美联社，档案

一名执业护士在一家计划生育诊所的办公室工作，她在那里进行咨询

米非司酮，阻断维持妊娠所需的孕酮激素，在头10周内给予女性。这种药丸与另一种叫做米索前列醇的药物一起服用，这种药物会导致抽筋和出血，从而排空子宫。

去年春天，美国食品和药物管理局停止了对米非司酮的亲自配药要求，引用了COVID的风险，并指出该药物自20多年前上市以来的良好安全记录。

女性仍然必须通过认证的医疗保健提供者获得避孕药。

虽然堕胎权利倡导者说，这一决定保护了妇女获得合法堕胎的隐私权，但反对者坚持认为这种做法是危险的，会危及妇女的生命。

“拜登政府的鲁莽举动将无数妇女和未出生的孩子置于危险之中。堕胎积极分子的长期愿望是把每一个邮局和药店都变成一个堕胎中心，”反堕胎组织苏珊·安东尼·李斯特的州政策主任苏·利贝尔说。

周四的决定并不意味着每个女性都能通过邮件获得避孕药。

根据跟踪各州堕胎药丸政策的古特马赫研究所的说法，19个州已经要求提供者在服用药丸时亲自在场，并禁止在开处方时进行远程医疗。

FDA lifts restriction on abortion pill, permanently allowing delivery by mail

The U.S. Food and Drug Administration on Thursday permanently lifted its restriction on the abortion pill mifepristone that required providers to dispense the drug in person, allowing it to be delivered by mail.

The decision is subject to state laws that can criminalize the practice. But the FDA move could still have significant consequences for women, particularly in rural areas where it might be harder for women to find a clinic or doctor that will administer the drug in person.

In its updated guidance online, the FDA cited the need to "reduce burden on patient access and thehealthcare delivery system."

Abortion rights groups cheered the move but said more needs to be done to ease access.

"While the action today will go a long way for people seeking care, other barriers remain and must be lifted once and for all," said Destiny Lopez, co-president of All* Above All.

Mifepristone, which blocks the hormone progesterone needed to support a pregnancy, is given to women within the first 10 weeks. The pill is taken with another drug called misoprostol, which causes cramping and bleeding to empty the uterus.

The FDA had stopped enforcing the in-person dispensing requirement for mifepristone last spring, citing the risks of COVID and noting the drug's strong safety record since it hit the market more than two decades ago.

Women still must obtain the pill through a certified health care provider.

While abortion-rights advocates say the decision protects a woman's right to privacy in obtaining a legal abortion, opponents insist the practice is dangerous and puts women's lives at risk.

"The Biden administration's reckless move puts countless women and unborn children in danger. Abortion activists' longtime wish has been to turn every post office and pharmacy into an abortion center," said Sue Liebel, state policy director for the antiabortion group Susan B. Anthony List.

Thursday's decision doesn't mean that every woman will be able to get the pill through the mail.

According to The Guttmacher Institute, which tracks state policies on the abortion pill, 19 states already require a provider to be physically present when administering the pill and prohibit telemedicine when prescribing it.